Skip to content
Open access

AbPACER: parent-aware, affinity-label-blind prioritization of affinity-matured scFv clones from phage-display NGS

Aug 2026 · bioRxiv · 0 citations · 27 references
Biology

TL;DR

AbPACER provides a campaign-specific, parent-aware framework for fixed-budget prioritization from affinity-label-blind phage-display NGS data and shows the highest mean recovery among learned methods in both retrospective campaigns.

Abstract

Background Affinity-maturation phage-display next-generation sequencing (NGS) yields more paired single-chain variable fragment clones than can be characterized experimentally, creating a fixed-budget prioritization problem. Read counts provide empirical support rather than direct affinity labels. We developed AbPACER (Antibody Parent-Aware Contextual Evidence Ranker), an affinity-label-blind neural ranker combining parent-relative mutation descriptors, frozen antibody-language-model context, and NGS evidence from related clones. AbPACER is campaign-adaptive rather than zero-shot: for each campaign, it is fitted to paired sequences and round-resolved R1–R3 counts before returning a 384-candidate assay list. We evaluated it in two retrospective phage-display campaigns and separately assessed its supervised mean-squared-error adaptation on AlphaSeq, denoted AbPACER-MSE. Results From frozen top-5% candidate sets containing 16,323 Fas-associated factor 1 (FAF1) and 7,487 vascular endothelial growth factor receptor (VEGFR) clones, each method ranked the complete target-specific set and selected 384 candidates. In FAF1, AbPACER recovered 2.00 ± 0.00 of seven retrospective panel clones, recovering two in every seed, compared with 1/7 by total count, 1.00 ± 0.00 by Ens-Grad CNN, 1.67 ± 1.15 by A2Binder-HL, and 1.33 ± 0.58 by AbAffinity. In VEGFR, AbPACER recovered 2.33 ± 0.58 of three panel clones, the highest observed learned-method mean, whereas total count recovered 3/3. No learned method was uniformly best at broader hypothetical budgets. On the public AlphaSeq common split of 11,670 fixed-test variants, AbPACER-MSE recovered 187.0 ± 2.6 of the true top-384, closely matching AbAffinity (188.0 ± 2.6) and exceeding A2Binder (175.7 ± 6.4) and Ens-Grad CNN (154.0 ± 6.1). AbPACER-MSE updated 1.378 million task-specific parameters, compared with 651.04 million for AbAffinity, and achieved Pearson 0.687 ± 0.003 and Spearman 0.652 ± 0.002. Conclusions AbPACER provides a campaign-specific, parent-aware framework for fixed-budget prioritization from affinity-label-blind phage-display NGS data. At the 384-candidate endpoint, it showed the highest mean recovery among learned methods in both retrospective campaigns. AbPACER-MSE closely matched AbAffinity in true top-384 recovery while updating substantially fewer task-specific parameters. These results motivate prospective evaluation of sequence-conditioned reranking as a complement to count-based prioritization.

Read PDF

Similar papers

Preprint Jul 2026

AbICL: In-Context Learning for Antigen-Specific Antibody Affinity Ranking

AbICL is proposed, an ICL framework for antigen-specific antibody affinity ranking that combines a pretrained structural encoder with a context ranking head and is trained with an episodic meta-training strategy that enables the model to leverage support demonstrations for test-time adaptation without gradient updates.

Zhiyuan Chen, Jing Hu, Junzhe Wang et al. · 0 citations
Book Open access Aug 2026

SAASBench: A Synthetic Antibody–antigen Specificity Benchmark

SAASBench provides a framework for evaluating the model's ability to estimate the specificity of a candidate antibody in relevant settings, indicating that strong performance on traditional affinity benchmarks does not automatically translate into reliable antibody specificity estimation in proteome-derived settings.

Dmitriy Umerenkov, Ivan Poddiakov · 0 citations
Open access Aug 2026

A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability.

The AIntibody challenge shows that AI can optimize antibodies in defined, biologically grounded regimes, in addition to highlighting critical gaps including affinity prediction and library-inspired antibody design and cross-task generalization.

M. Erasmus, Daniel Bedinger, Elizabeth Hopkins et al. · 0 citations
#protein folding Preprint Aug 2026

CIR-DDG: backbone-agnostic residual correction of antibody-antigen affinity changes with explicit cross-chain geometry

CIR-DDG, a lightweight residual adapter that combines a fixed base prediction with 22 interpretable descriptors of cross-chain distance, contact density and site--partner context, is introduced, showing that the learned geometric correction generalizes beyond SKEMPI thermodynamic measurements.

Weizhen Yu, Zhi-Heng Zou, Yonggui Huang et al. · 0 citations
Open access Aug 2026

Focused framework sampling recovers binding-positive humanized anti-amyloid-β antibodies in a single sorting round

Therapeutic antibody development requires workflows that integrate antigen-reactive clone discovery with efficient humanization and early developability assessment. Here, we combined immune yeast fragment antigen-binding (Fab) display with single-round focused humanization and applied the workflow to antibodies against amyloid-β (Aβ)-derived preparations. Immunization with Aβ1-42 aggregate preparations generated a Fab-display library with a diversity of approximately 3.5 × 108. Magnetic enrichment followed by fluorescence-activated cell sorting (FACS) identified three sequence-distinct immunoglobulin G (IgG)-format candidates, of which CLAB17 and CLAB45 were advanced to humanization. Structure-guided libraries sampled framework positions predicted to support complementarity-determining regions (CDRs) or heavy-and light-chain variable-domain packing, and a single FACS round recovered binding-positive variants CLAB17-h2 and CLAB45-h8. Both retained the parental CDRs and showed increased predicted humanness, favorable computational developability triage profiles, and high purity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). By enzyme-linked immunosorbent assay (ELISA), CLAB17-h2 showed a lower apparent half-maximal effective concentration (EC50) for Aβ1-42AggreSure, whereas CLAB45-h8 showed a lower apparent EC50 for pyroglutamate-modified Aβ3-42 (AβpE3-42). Because the preparations were not resolved into defined assembly states, these antibodies are considered Aβ-preparation-binding rather than aggregate-state-selective candidates. This workflow provides a practical route from immune-repertoire discovery to binding-positive humanized antibodies.

Youngju Kim, Hayoung Kwon, Jimin Song et al. · 0 citations
Open access Aug 2026

AbAgKer: a unified semi-supervised framework for antigen-antibody binding affinity and kinetics prediction

This work designs a biological prior-guided feature fusion framework that integrates pseudo-structural epitope knowledge and CDR-specific attention mechanisms via a mixture-of-experts architecture to effectively capture complex binding landscapes in antibody screening and drug residence time analysis.

G. Luo, Junkai Wang, Sizhe Zhang et al. · 0 citations